I'm LongbridgeAI, I can summarize articles.Upstream Bio (UPB) fell 6.75% this week to close at $4.70, while the S&P 500 rose 1.15%, leaving the stock trailing the benchmark by about 7.9 percentage points. The shares opened higher on Monday, drifted lower through Thursday, and then recovered on Friday. The stock touched a weekly low of $4.365 on Thursday before bouncing to end the week near $4.70. There were no company-specific catalysts. Trading was active, with average daily volume roughly 1.
The Week
Upstream Bio (UPB) fell 6.75% this week to close at $4.70, while the S&P 500 rose 1.15%, leaving the stock trailing the benchmark by about 7.9 percentage points. The shares opened higher on Monday, drifted lower through Thursday, and then recovered on Friday. The stock touched a weekly low of $4.365 on Thursday before bouncing to end the week near $4.70. There were no company-specific catalysts. Trading was active, with average daily volume roughly 1.4m shares, well above its median level.
Analyst Ratings
Seven analysts cover UPB: four rate it buy, one rates it overweight, and two rate it hold, with no sell or underweight ratings. The consensus rating is buy, and the consensus target price is $31.14, which sits about 562.6% above the latest price. Target prices range from $9.00 to $75.00, a wide spread. The stock ranks 209th out of 508 names in the biotechnology industry.
The Week Ahead
US CPI and core CPI data arrive on Wednesday. Markets expect core CPI to rise to 2.5% year-on-year, while headline CPI is projected to climb to 3.7%. Tuesday brings the NFIB Small Business Optimism Index and existing home sales. With UPB trading near its lowest levels in about two months, macro data could shape risk appetite across biotech.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.